A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

Mariane Teodoro Fernandes MD, Jacob J Adashek BA, Carmelia Maria Noia Barreto MD, Ana Cláudia Barbin Spinosa MD, Barbara de Souza Gutierres MSc, Gilberto Lopes MD, MBA, FAMS, Auro del Giglio MD, PhD, Pedro Nazareth Aguiar Jr MD, MSc

Abstract

In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. All of the approved drugs exhibit progression-free survival benefit when compared to standard of care and generally have less adverse events compared to traditional chemotherapeutic options. The treatment of HR+/HER2- advanced breast cancer is a continuously evolving landscape, and the addition of CDK4/6 inhibitors is the newest mechanism for treatment. In this review, we summarize all available data, highlight the unanswered questions, and discuss pharmacological differences between each CDK4/6 inhibitor.

Article Details

Article Type

Review

DOI

10.7573/dic.212555

Publication Dates

Accepted: ; Published: .

Citation

Fernandes MT, Adashek JJ, Noia Barreto CM, Barbin Spinosa AC, de Souza Gutierres B, Lopes G, del Giglio A, Aguiar PN Jr. A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors. Drugs in Context 2018; 7: 212555. DOI: 10.7573/dic.212555

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.